Barclays’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $528K | Sell |
44,067
-23,360
| -35% | -$194K | ﹤0.01% | 3189 |
|
|
2026
Q1 | $565K | Sell |
67,427
-96,994
| -59% | -$1.02M | ﹤0.01% | 3120 |
|
|
2025
Q4 | $2.37M | Sell |
164,421
-61,519
| -27% | -$767K | ﹤0.01% | 2817 |
|
|
2025
Q3 | $2.18M | Sell |
225,940
-13,595
| -6% | -$120K | ﹤0.01% | 2826 |
|
|
2025
Q2 | $1.97M | Buy |
239,535
+119,876
| +100% | +$1M | ﹤0.01% | 2856 |
|
|
2025
Q1 | $856K | Sell |
119,659
-7,406
| -6% | -$55.1K | ﹤0.01% | 3199 |
|
|
2024
Q4 | $982K | Buy |
127,065
+11,041
| +10% | +$104K | ﹤0.01% | 3390 |
|
|
2024
Q3 | $1.22M | Buy |
116,024
+67,948
| +141% | +$828K | ﹤0.01% | 3234 |
|
|
2024
Q2 | $562K | Sell |
48,076
-1,376
| -3% | -$21.4K | ﹤0.01% | 2976 |
|
|
2024
Q1 | $1.04M | Sell |
49,452
-62,552
| -56% | -$1.11M | ﹤0.01% | 3091 |
|
|
2023
Q4 | $2.01M | Buy |
112,004
+30,197
| +37% | +$532K | ﹤0.01% | 2915 |
|
|
2023
Q3 | $1.35M | Sell |
81,807
-8,468
| -9% | -$153K | ﹤0.01% | 2138 |
|
|
2023
Q2 | $1.8M | Buy |
90,275
+23,527
| +35% | +$453K | ﹤0.01% | 1953 |
|
|
2023
Q1 | $1.26M | Sell |
66,748
-29,860
| -31% | -$661K | ﹤0.01% | 2556 |
|
|
2022
Q4 | $2.19M | Buy |
96,608
+11,463
| +13% | +$259K | ﹤0.01% | 2206 |
|
|
2022
Q3 | $2.25M | Buy |
85,145
+70,215
| +470% | +$2.08M | ﹤0.01% | 1671 |
|
|
2022
Q2 | $369K | Sell |
14,930
-32,616
| -69% | -$815K | ﹤0.01% | 3070 |
|
|
2022
Q1 | $1.58M | Sell |
47,546
-19,827
| -29% | -$551K | ﹤0.01% | 2052 |
|
|
2021
Q4 | $2.2M | Sell |
67,373
-256
| -0.4% | -$8.72K | ﹤0.01% | 2330 |
|
|
2021
Q3 | $2.83M | Buy |
67,629
+32,591
| +93% | +$1.17M | ﹤0.01% | 2059 |
|
|
2021
Q2 | $1.36M | Sell |
35,038
-35,460
| -50% | -$1.27M | ﹤0.01% | 2460 |
|
|
2021
Q1 | $2.4M | Buy |
70,498
+29,944
| +74% | +$1.28M | ﹤0.01% | 2110 |
|
|
2020
Q4 | $1.84M | Sell |
40,554
-31,215
| -43% | -$1.09M | ﹤0.01% | 2299 |
|
|
2020
Q3 | $1.98M | Sell |
71,769
-17,194
| -19% | -$561K | ﹤0.01% | 2118 |
|
|
2020
Q2 | $3.27M | Sell |
88,963
-1,162
| -1% | -$43.3K | ﹤0.01% | 1699 |
|
|
2020
Q1 | $2.92M | Sell |
90,125
-96,543
| -52% | -$4.02M | ﹤0.01% | 1925 |
|
|
2019
Q4 | $7.65M | Buy |
186,668
+125,679
| +206% | +$4.96M | ﹤0.01% | 1598 |
|
|
2019
Q3 | $2.17M | Sell |
60,989
-7,288
| -11% | -$295K | ﹤0.01% | 2762 |
|
|
2019
Q2 | $3.51M | Sell |
68,277
-14,702
| -18% | -$734K | ﹤0.01% | 2245 |
|
|
2019
Q1 | $4.76M | Buy |
82,979
+48,106
| +138% | +$2.38M | ﹤0.01% | 1697 |
|
|
2018
Q4 | $1.46M | Buy |
34,873
+1,135
| +3% | +$66.6K | ﹤0.01% | 2725 |
|
|
2018
Q3 | $2.55M | Buy |
33,738
+15,860
| +89% | +$1.14M | ﹤0.01% | 2591 |
|
|
2018
Q2 | $1.28M | Sell |
17,878
-2,637
| -13% | -$126K | ﹤0.01% | 3002 |
|
|
2018
Q1 | $614K | Buy |
20,515
+4,837
| +31% | +$141K | ﹤0.01% | 3746 |
|
|
2017
Q4 | $521K | Buy |
15,678
+3,317
| +27% | +$99.9K | ﹤0.01% | 3785 |
|
|
2017
Q3 | $407K | Buy |
12,361
+2,440
| +25% | +$54.9K | ﹤0.01% | 3815 |
|
|
2017
Q2 | $196K | Buy |
9,921
+5,429
| +121% | +$105K | ﹤0.01% | 4378 |
|
|
2017
Q1 | $86K | Sell |
4,492
-1,063
| -19% | -$20.5K | ﹤0.01% | 4997 |
|
|
2016
Q4 | $103K | Buy |
5,555
+5,428
| +4,274% | +$104K | ﹤0.01% | 4723 |
|
|
2016
Q3 | $2K | Buy |
+127
| New | +$1.4K | ﹤0.01% | 6264 |
|
|
2016
Q1 | – | Sell |
-108
| Closed | -$2K | – | 6391 |
|
|
2015
Q4 | $2K | Buy |
+108
| New | +$2.14K | ﹤0.01% | 5760 |
|
Other funds holding RGNX
RG
Barclays's RGNX Position: Q2 2026 in Review
Barclays reduced its Regenxbio (RGNX) stake by 35% in Q2 2026, selling an estimated $194K and leaving 44,067 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.
Barclays first reported a position in RGNX in Q4 2015 and has held it in 41 quarters since. The position peaked at $7.65M in Q4 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Barclays held 44,067 shares of Regenxbio worth $528K as of Q2 2026.
- Barclays sold 23,360 Regenxbio shares in Q2 2026, an estimated $194K.
- Regenxbio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3189 holding.
- Barclays first reported a position in Regenxbio in Q4 2015 and has held it in 41 quarters since.
- Barclays's Regenxbio position peaked at $7.65M in Q4 2019.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.